Comparative Pharmacology
Head-to-head clinical analysis: FABIOR versus ISOTRETINOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABIOR versus ISOTRETINOIN.
FABIOR vs ISOTRETINOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), inducing differentiation and apoptosis of keratinocytes.
Reduces sebum production, inhibits sebaceous gland activity, and induces apoptosis in sebocytes. Binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) to regulate gene expression.
FABIOR (tazarotene) foam, 0.1%: Apply a thin layer once daily in the evening to affected areas of the face, scalp, or trunk.
0.5-1 mg/kg/day orally in two divided doses for 15-20 weeks; cumulative dose 120-150 mg/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 24-26 hours, supporting once-daily dosing.
Clinical Note
moderateIsotretinoin + Estrone sulfate
"The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Estramustine
"The therapeutic efficacy of Estramustine can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Dienogest
"The therapeutic efficacy of Dienogest can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Medroxyprogesterone acetate
Terminal elimination half-life is approximately 20 hours (range 10-30 hours) for the parent drug. Clinical significance: steady-state achieved in ~5 days with repeated dosing; prolongation in renal impairment is minimal.
Primarily hepatic metabolism via CYP450; renal excretion of metabolites accounts for <1% of dose as unchanged drug. Fecal elimination is the major route (approximately 90%).
Primarily hepatic metabolism; metabolites excreted in urine (65-80%) and feces (15-35%). Less than 1% excreted unchanged in urine.
Category C
Category D/X
Retinoid
Retinoid
"The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin."